ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m

Regulatory News:

ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today carries out a capital increase with the removal of preferential subscription rights (“PSR”) for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580,643 new shares at a subscription price of 3.10 euros (the “Issuance”).

Terms and conditions of the Issue

Following the Issuance decision taken on December 16, 2025, the Chief Executive Officer today confirmed the full subscription of 580,643 new shares at a price of €3.10 per share (representing a 10% discount on the closing price on December 16, 2025). This issue represents approximately 1.66% of the share capital on the date of the Issue decision.

This transaction is part of a capital increase with the removal of preferential subscription rights in favor of persons belonging to specific categories, decided by the Board of Directors on December 16, 2025, acting on the basis of the delegation granted by the General Meeting of June 26, 2025, under its fourteenth extraordinary resolution.

The total amount of the capital increase is €1,799,993.30 (including €29,032.15 in nominal value and a share premium of €1,770,961.15). The new shares will carry current dividend rights, will be treated as existing shares and will enjoy the same rights. They will be subject to all statutory provisions and will be admitted to trading on Euronext on the same listing line as the existing shares.

Shareholders’ capital

The number of shares issued represents approximately 1.66% of the number of shares outstanding prior to the Offering and 1.64% after the Offering.

For example, a shareholder who held a number of shares representing 1% of ABIONYX Pharma's capital prior to the Offering will represent 0.98% of the share capital after the Offering.

Shareholding structure after the Offering

	Non dilutive basis				Dilutive basis (1)
Shareholders	Number of shares	% of capital	Number of voting rights	% of voting rights	Number of shares